Xvivo Perfusion
XVIVO Perfusion AB is a Swedish medical technology company specialized in organ preservation, evaluation, and perfusion systems for organ transplantation procedures. The company develops perfusion machines, preservation solutions, and single-use disposable sets for lungs, hearts, and livers awaiting transplantation. Primary revenue streams consist of machine device sales, organ preservation solution consumables, single-use tubing kits, and clinical support services. XVIVO Perfusion serves transplant centers, university hospitals, organ procurement organizations, and thoracic surgery clinics globally. The enterprise commands a dominant global market position in warm perfusion technology and lung preservation systems for organ transplantation. XVIVO Perfusion AB is headquartered in Gothenburg, Sweden, and its common shares are listed on Nasdaq Stockholm.
17 of the funds FundTelligence covers report a position in Xvivo Perfusion.
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 17
Funds holding Xvivo Perfusion
- Nordea Innovation Sustainable Stars — Nordea Funds · 5.65 % (full portfolio disclosed, June 2026)
- TIN Ny Teknik — Tin Fonder · 5.49 % (full portfolio disclosed, June 2026)
- Kavaljer Quality Focus — Kavaljer · 2.8 % (partially disclosed portfolio, October 2026)
- Case Gaia Microcap — Case · 2.46 % (full portfolio disclosed, June 2026)
- Schroder ISF Nordic Smaller Companies — Schroders · 1.53 % (full portfolio disclosed, June 2026)
- Schroder ISF Nordic Micro Cap — Schroders · 1.39 % (full portfolio disclosed, June 2026)
- Lannebo Sweden Micro Cap — Lannebo · 0.81 % (full portfolio disclosed, June 2026)
- Storebrand Sverige Småbolag Plus — Storebrand · 0.18 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 17 funds holding it.